Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab (Gazyva, Genentech) for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
The regimen was evaluated in Study BGB-3111-212 (ClinicalTrials.gov Identifier: NCT03332017), an open-label, multicenter, randomized trial that enrolled 217 adult patients with relapsed or